[go: up one dir, main page]

GT200200070A - Composiciones que contienen imidazotriazinona para administracion nasal - Google Patents

Composiciones que contienen imidazotriazinona para administracion nasal

Info

Publication number
GT200200070A
GT200200070A GT200200070A GT200200070A GT200200070A GT 200200070 A GT200200070 A GT 200200070A GT 200200070 A GT200200070 A GT 200200070A GT 200200070 A GT200200070 A GT 200200070A GT 200200070 A GT200200070 A GT 200200070A
Authority
GT
Guatemala
Prior art keywords
imidazotriazinone
compositions containing
nasal administration
gmpc
phosphodiesterases
Prior art date
Application number
GT200200070A
Other languages
English (en)
Inventor
Peter Serno
Andreas Ohm
Wolfgang Barth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200200070A publication Critical patent/GT200200070A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPOSICIONES QUE CONTIENEN IMIDAZOTRIAZINONA PARA ADMINISTRACION NASAL DE FORMULA GENERAL (I) EN DONDE R1,R2,R3,R4,R5,R6, SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE. ESTOS COMPUESTOS VAN A CONTENER UNA PEQUEÑA CANTIDAD DE ANESTESICO LOCAL JUNTO CON LA IMIDAZOTRIAZINONA QUE COMO INHIBIDOR DE FOSFODIESTERASAS (PDE GMPC) SON UTILES EN LA DISFUNCION ERECTIL MASCULINA.
GT200200070A 2001-04-12 2002-04-11 Composiciones que contienen imidazotriazinona para administracion nasal GT200200070A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10118306A DE10118306A1 (de) 2001-04-12 2001-04-12 Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation

Publications (1)

Publication Number Publication Date
GT200200070A true GT200200070A (es) 2003-01-31

Family

ID=7681379

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200200070A GT200200070A (es) 2001-04-12 2002-04-11 Composiciones que contienen imidazotriazinona para administracion nasal

Country Status (25)

Country Link
US (2) US6740306B2 (es)
EP (1) EP1381368A2 (es)
JP (1) JP2004525968A (es)
KR (1) KR20030087072A (es)
CN (1) CN1537004A (es)
AR (1) AR035821A1 (es)
BG (1) BG108245A (es)
BR (1) BR0208813A (es)
CA (1) CA2443639A1 (es)
CZ (1) CZ20032752A3 (es)
DE (1) DE10118306A1 (es)
DO (1) DOP2002000373A (es)
EC (1) ECSP034795A (es)
EE (1) EE200300501A (es)
GT (1) GT200200070A (es)
HU (1) HUP0303877A3 (es)
IL (1) IL158255A0 (es)
MX (1) MXPA03009314A (es)
NO (1) NO20034556L (es)
PE (1) PE20021035A1 (es)
PL (1) PL363033A1 (es)
RU (1) RU2003133143A (es)
SK (1) SK12682003A3 (es)
UY (1) UY27256A1 (es)
WO (1) WO2002083674A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE348618T1 (de) * 2001-05-09 2007-01-15 Bayer Healthcare Ag Neue verwendung von 2-(2-ethoxy-5-(4-methyl- piperazin-1-sulfonyl)-phenyl)-5-methyl-7-propyl 3h-imidazo(5,1-f)(1,2,4)triazin-4-on
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
JP4966204B2 (ja) * 2004-12-23 2012-07-04 ロックスロ ファーマ， インコーポレイテッド ケトロラクの鼻腔内投与のための治療用組成物
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
DE102005009240A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
WO2007002125A1 (en) * 2005-06-23 2007-01-04 Schering Corporation Rapidly absorbing oral formulations of pde5 inhibitors
US20090186896A1 (en) * 2005-09-29 2009-07-23 Bayer Healthcare Ag PDE Inhibitors and Combinations Thereof for the Treatment of Urological Disorders
CA2689638A1 (en) * 2007-06-13 2008-12-18 Bayer Schering Pharma Aktiengesellschaft Pde inhibitors for the treatment of hearing impairment
CN102137656A (zh) * 2008-06-13 2011-07-27 罗克斯罗制药公司 用于鼻内投予的酮咯酸医药调配物
US8277781B2 (en) * 2009-03-13 2012-10-02 Luitpold Pharmaceuticals, Inc. Device for intranasal administration
US8551454B2 (en) * 2009-03-13 2013-10-08 Luitpold Pharmaceuticals, Inc. Device for intranasal administration
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
WO2020006606A1 (en) * 2018-07-05 2020-01-09 Helium 3 Resources Pty Ltd A pharmaceutical composition and method of use of same
SE542968C2 (en) * 2018-10-26 2020-09-22 Lindahl Anders Treatment of osteoarthritis
AU2021280285A1 (en) * 2020-05-26 2023-02-02 Strategic Drug Solutions, Inc. Formulations and methods for treating erectile dysfunction

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4602099A (en) * 1973-04-02 1986-07-22 Merrell Dow Pharmaceuticals Inc. Antirhinovirus agents
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB9514465D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9514473D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
DE69720542D1 (de) 1996-05-31 2003-05-08 Mochida Pharm Co Ltd PYRIDOCARBAZOL DERIVATE DIE EINEN cGMP-PDE INHIBILIERENDEN EFFEKT HABEN
GB2315673A (en) * 1996-08-01 1998-02-11 Merck & Co Inc Treatment of migraine
AU739417B2 (en) * 1997-05-29 2001-10-11 Mochida Pharmaceutical Co., Ltd. Therapeutic agent for erection dysfunction
JP2001517628A (ja) 1997-09-23 2001-10-09 イーライ・リリー・アンド・カンパニー 注意欠陥／多動障害の治療法
HRP20020585B1 (hr) 1997-11-12 2013-02-28 Bayer Schering Pharma Aktiengesellschaft 2-fenil supstituirani imidazotriazinoni kao inhibitori fosfodiesteraze
TWI223598B (en) * 1998-06-22 2004-11-11 Pfizer Ireland Pharmaceuticals An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate
AU4717299A (en) * 1998-06-26 2000-01-17 Nastech Pharmaceutical Company, Inc Nasal delivery of sildenafil citrate
CN1526448A (zh) * 1998-12-14 2004-09-08 ���ռ�ҩ��ɷ����޹�˾ 用于治疗肛门直肠病的药物和方法

Also Published As

Publication number Publication date
EE200300501A (et) 2003-12-15
ECSP034795A (es) 2003-12-01
IL158255A0 (en) 2004-05-12
CZ20032752A3 (cs) 2004-01-14
RU2003133143A (ru) 2005-04-10
US20030022894A1 (en) 2003-01-30
US20040248891A1 (en) 2004-12-09
WO2002083674A3 (de) 2003-01-09
BG108245A (en) 2005-01-31
CA2443639A1 (en) 2002-10-24
NO20034556L (no) 2003-12-10
PL363033A1 (en) 2004-11-15
DOP2002000373A (es) 2002-11-30
PE20021035A1 (es) 2002-11-29
BR0208813A (pt) 2004-03-09
DE10118306A1 (de) 2002-10-17
SK12682003A3 (sk) 2004-03-02
WO2002083674A2 (de) 2002-10-24
HUP0303877A2 (hu) 2004-03-29
JP2004525968A (ja) 2004-08-26
AR035821A1 (es) 2004-07-14
US6740306B2 (en) 2004-05-25
UY27256A1 (es) 2002-11-29
NO20034556D0 (no) 2003-10-10
HUP0303877A3 (en) 2005-05-30
CN1537004A (zh) 2004-10-13
KR20030087072A (ko) 2003-11-12
EP1381368A2 (de) 2004-01-21
MXPA03009314A (es) 2004-03-10

Similar Documents

Publication Publication Date Title
GT200200070A (es) Composiciones que contienen imidazotriazinona para administracion nasal
PA8551001A1 (es) Nuevos compuestos
AR053412A1 (es) Compuestos inhibidores de la interaccion entre mdm2 y p53, un metodo de preparadcion, composicion farmaceutica y uso del compuesto para fabricar medicamentos
MXPA02011426A (es) Derivados de b-carbolina utiles como inhibidores de fosfodiesterasa.
SV1998000008A (es) Inhibisores de sulfamida-metaloproteasa. ref. ran 4070\114
GT200400092A (es) Preparacion y uso de derivados de alquilarilo para el tratamiento de la obesidad
GT200500008A (es) Intermediarios de quinolina como inhibidores de receptores de tirosina quinasas y la sintesis de los mismos
PA8593001A1 (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
GT200100137A (es) Pro-drogas de derivados de 4-fenil-piridina.
DE60314623D1 (de) Substituierte pyrazolopyrimidine
GT200100132A (es) Derivados de pirazol
ATE369370T1 (de) Substituierte 2h-(1,2,4)triazolo(4,3-a)pyrazine als gsk-3-inhibitoren
PA8596901A1 (es) Inhibidores de p38 y metodos de uso de ellos
DE602005014382D1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb-kinaseinhibitoren
GT200400133A (es) Derivados de pirrolo[3,4-c] pirazol activos como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden
CY1107747T1 (el) Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
AR063925A1 (es) Antibacteriales 5-hidroximetil -oxazolidin-2-ona composicion farmaceutica que los comprende y su uso para tratar o prevenir infecciones bacterianas
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
PA8575601A1 (es) Procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso
ATE368666T1 (de) Pyrazolopyrimidinone und ihre verwendung als pde inhibitoren
GT200100251A (es) Procedimiento para la preparacion de imidazotriazinonas substituidas con sulfonamida
NO20033959L (no) Benzimidazoler som er nyttige i behandling av seksuell dysfunksjon
UY27980A1 (es) Indoles 2,7-sustituidos
PA8623101A1 (es) Compuestos farmaceuticamente activos
PA8589801A1 (es) Aminoalcoxiindoles